Building IPO Valuation Model Assumptions from Prospectus Data Points

The Hong Kong IPO market in H1 2025 has registered 29 new listings on the Main Board, raising a combined HKD 37.8 billion, according to HKEX data. This represents a 42% increase in proceeds year-on-year, driven by a cluster of large-cap consumer and healthcare issuers. Concurrently, the SFC’s revised Code of Conduct for Sponsors (effective 1 January 2025) has tightened due diligence requirements on revenue recognition and connected transactions, forcing underwriters to demand more granular prospectus disclosures. For analysts and investment bankers building valuation models, the prospectus has evolved from a static legal document into a dynamic dataset requiring systematic extraction. The challenge is no longer finding data, but isolating the 15-20 high-signal assumptions—addressable market growth rates, margin trajectories, and working capital cycles—that drive 90% of a model’s output variance. This article provides a structured methodology for converting prospectus data points into defensible valuation assumptions, referencing specific HKEX and SFC requirements.

Extracting the Revenue Engine: TAM, Growth Drivers, and Trajectory Assumptions

The revenue model is the most contested assumption in any IPO valuation, particularly for issuers with less than three years of profitable operations. The prospectus’s “Industry Overview” section, often commissioned from a third-party research firm like Frost & Sullivan or Euromonitor, provides the baseline total addressable market (TAM) figures. However, these reports are commissioned by the issuer and typically present an optimistic scenario. The analyst’s task is to triangulate these figures against independent sources, such as HKMA’s Monthly Statistical Bulletin for financial services issuers or the Census and Statistics Department’s trade data for consumer goods companies.

Decomposing Revenue Growth into Volume and Price

A common error is applying a single blended growth rate to historical revenue. The prospectus’s “Management Discussion and Analysis” (MD&A) section, typically found in Part II of the HKEX listing document, breaks down revenue by segment, channel, and geography. For a Main Board consumer issuer filing in 2025, the analyst should isolate volume growth (units sold or number of customers) from price/mix changes. For example, a prospectus might state revenue grew 18.3% in FY2024, but the MD&A reveals that volume contributed 12.1% and average selling price (ASP) contributed 6.2%. The volume growth assumption should be anchored to the TAM growth rate (e.g., 8.5% CAGR from the industry report), adjusted for the issuer’s market share trajectory. The ASP assumption should reflect the issuer’s pricing power, which can be inferred from the gross margin trend and any disclosed pricing strategies in the “Business” section.

Linking Revenue Drivers to Non-Financial KPIs

Many prospectuses, particularly those for new economy issuers on the Main Board under Chapter 18C, include non-financial KPIs such as gross transaction value (GTV), monthly active users (MAUs), or average revenue per user (ARPU). The SFC’s revised Sponsor Code (paragraph 5.3) explicitly requires sponsors to verify these KPIs against independent data sources. For valuation purposes, the analyst should build a waterfall model that maps MAU growth to ARPU expansion and then to total revenue. For instance, a 2024 prospectus for a Chinese e-commerce platform disclosed MAU growth of 22.4% and ARPU growth of 8.1%, yielding a 32.3% revenue increase. The valuation assumption for Year 1 post-IPO should decelerate MAU growth to 15-18% (reflecting market saturation) and ARPU growth to 4-6% (reflecting competitive pressure), producing a revenue growth range of 19-24%. This disciplined decomposition prevents the common error of extrapolating a 30%+ top-line growth rate for five years.

Building the Margin Structure: Gross Profit, Operating Leverage, and One-Time Adjustments

The profit and loss statement in the prospectus’s “Financial Information” section provides the raw data, but the IPO valuation model requires normalisation. HKEX Listing Rule 11.10 requires disclosure of the last three financial years, but the first year’s data often includes pre-IPO restructuring costs, share-based compensation, and sponsor fees that distort underlying margins.

Normalising Gross Profit for Cost of Revenue Components

Gross margin is the most reliable indicator of business model sustainability. The prospectus’s notes to the financial statements break down cost of revenue into raw materials, direct labour, manufacturing overheads, and logistics. For a manufacturing issuer, the analyst should calculate the gross margin trajectory excluding the impact of one-off supplier discounts or inventory write-downs. A 2025 prospectus for a medical device company showed a gross margin of 62.4% in FY2024, but the notes revealed that this included a HKD 12.3 million reversal of an inventory provision. The normalised gross margin was 59.8%. The valuation assumption should use this normalised figure as the base, then apply a 50-100 bps annual expansion for economies of scale, capped at the industry peer median of 64.5% (from comparable listed companies’ annual reports).

Modelling Operating Leverage Through SG&A Ratios

Selling, general, and administrative (SG&A) expenses as a percentage of revenue determine how much of the revenue growth flows through to operating profit. The prospectus’s “Segment Information” section often allocates SG&A by function. For a consumer brand issuer, the analyst should separate marketing spend (typically 15-25% of revenue for growth-stage companies) from administrative overhead (5-8%). The valuation assumption should model marketing spend as a percentage of revenue that declines by 200-300 bps per year as brand awareness matures, while administrative overhead remains flat in absolute terms or grows at half the revenue growth rate. This creates the operating leverage that justifies a higher valuation multiple. For example, a 2024 prospectus for a beverage company showed an SG&A ratio of 38.2% in FY2022, declining to 31.5% in FY2024. The model assumption for FY2025-2027 should project a further decline to 26-28%, consistent with the industry peer average of 24.7%.

Capital Structure and Cash Flow: The Balance Sheet Inputs to DCF Valuation

A discounted cash flow (DCF) model is only as good as its terminal value assumption, which is heavily influenced by the weighted average cost of capital (WACC) and the reinvestment rate. The prospectus’s “Capitalisation and Indebtedness” section, required under HKEX Listing Rule 11.08, provides the pre-IPO capital structure. The analyst must adjust this for the IPO proceeds and the intended use of funds.

Calculating the Post-IPO WACC

The cost of equity is derived from the risk-free rate (typically the 10-year HKD or USD government bond yield, currently 3.85% as of June 2025), the equity risk premium (ERP) for Hong Kong (estimated at 5.5-6.5% by Duff & Phelps), and the issuer’s beta. The prospectus does not provide beta, but the “Risk Factors” section (Part I of the listing document) lists industry-specific risks that inform the beta adjustment. For a biotech issuer with no revenue, the beta should be set at 1.5-2.0. For a mature utility issuer, 0.8-1.0 is appropriate. The cost of debt can be estimated from the interest rate on any disclosed bank loans or bonds in the “Indebtedness” section. For a typical Hong Kong Main Board issuer with a BB+ credit profile, the pre-tax cost of debt is approximately 6.0-7.5%. The post-tax WACC, assuming a 16.5% Hong Kong profits tax rate, then drives the discount rate for the DCF.

Modelling Capex and Working Capital from Cash Flow Statements

The prospectus’s “Statement of Cash Flows” is often the most underutilised section. The analyst should calculate the historical capex-to-revenue ratio and the cash conversion cycle (days sales outstanding + days inventory outstanding – days payables outstanding). For a manufacturing issuer, the capex ratio might be 8-12% of revenue, while for a software issuer, it could be 3-5%. The working capital assumption should be modelled as a percentage of revenue growth. A 2025 prospectus for a logistics company showed a cash conversion cycle of 42 days in FY2024. The model assumption should project this declining to 35 days by FY2027, reflecting improved payment terms with suppliers as the company scales. This release of working capital adds to free cash flow and increases the DCF valuation by an estimated 8-12%.

Benchmarking to Peers: The Role of Comparable Company Analysis

The comparable company analysis (comps) is the most commonly used valuation method in Hong Kong IPO pricing, as it provides a market-implied multiple that underwriters can defend to institutional investors. The prospectus’s “Industry Overview” section lists competitors, but the analyst must select the appropriate peer group and apply the correct multiples.

Selecting Multiples: P/E, EV/EBITDA, and P/S for Different Stages

For profitable issuers, the price-to-earnings (P/E) multiple is standard. The prospectus’s historical net profit, adjusted for one-time items, provides the base. The analyst should calculate the peer group’s median trailing P/E and forward P/E (using consensus estimates from Bloomberg or FactSet). For a 2025 consumer IPO, the peer median trailing P/E might be 22.5x, with a forward P/E of 18.2x. The issuer’s valuation assumption should be at a discount of 10-20% to the peer median, reflecting the illiquidity premium and lack of a trading history. For unprofitable issuers, the enterprise value-to-sales (EV/Sales) multiple is used. The prospectus’s revenue for the most recent fiscal year, projected forward, determines the multiple.

Adjusting for Growth and Margin Differences

A pure multiple comparison is insufficient. The analyst must adjust for differences in growth rates and margins. The PEG ratio (P/E divided by earnings growth rate) provides a standardised metric. For example, if the issuer has a projected earnings growth rate of 25% and the peer median is 15%, the issuer’s P/E multiple should be higher by a factor of (25/15) = 1.67x, assuming a PEG ratio of 1.0x. Similarly, an issuer with a gross margin of 60% versus a peer median of 45% should command a higher EV/EBITDA multiple. The prospectus’s “Financial Summary” table allows the analyst to calculate these differentials precisely.

Actionable Takeaways

1. Use the MD&A section to decompose revenue growth into volume and price components, then anchor volume growth to the TAM CAGR from the industry report, adjusted for market share trajectory.
2. Normalise gross profit by removing one-time inventory provisions and supplier discounts disclosed in the notes to the financial statements, then apply a 50-100 bps annual margin expansion cap.
3. Build the post-IPO WACC using the prospectus’s capitalisation table, the current HKD 10-year bond yield of 3.85%, and a beta derived from the risk factors section, with a 5.5-6.5% Hong Kong ERP.
4. Model working capital changes by calculating the historical cash conversion cycle from the statement of cash flows and projecting a 5-10 day improvement over three years as the company scales.
5. Apply a 10-20% discount to the peer median P/E or EV/Sales multiple to account for IPO illiquidity and adjust the multiple further using the issuer’s relative growth rate and gross margin differential.